Background: The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results.
Introduction
Chemotherapy-induced nausea and vomiting (CINV) is a major issue for cancer patients undergoing oncological treatment, due to the intrinsic emetogenicity of chemotherapeutic agents [1] . Some of these (e.g. high-dose cyclophosphamide, carmustine, dacarbazine, mechlorethamine, streptozotocine and cisplatin), can lead to a >90% incidence of CINV in patients without an adequate antiemetic prophylaxis [2] .
Ginger (Zingiber officinalis) may counteract nausea and gastrointestinal discomfort; however, studies carried out in the CINV setting are limited. Marx et al. [3] identified only seven trials on this topic, five with small sample size. In a study by Ryan et al. [4] on 576 patients, ginger supplementation (0.5-1.0 g) significantly reduced the severity of acute CINV. However, design inadequacies, heterogeneity of the population, poor quality of tested products, and the nonstandardized preparations of ginger limit the possibility to offer generalizable results [3, 5] . Therefore, new studies on this topic appear warranted.
This randomized, double-blind, placebo-controlled, multicenter study evaluates the efficacy of ginger in reducing the incidence and intensity of delayed nausea in patients on high-dose cisplatin and standard antiemetic therapy for high emetogenic chemotherapy (HEC).
Patients and methods

Study setting and design
This was a randomized, double-blind, placebo-controlled trial conducted at six Italian oncological centers. The study (ClinicalTrials.gov identifier: NCT01887314) was approved by the Independent Ethic Committee (IEC) of the Fondazione IRCCS, Istituto Nazionale dei Tumori Milano, and by the IECs of all other centers. It was conducted in compliance with the Declaration of Helsinki and all relevant regulations. Patients provided written informed consent before inclusion. The first subject carried out Visit 1 (Screening Visit) on June 2013 and the last subject completed the study on April 2015. Overall, the study lasted 673 days (22.4 months).
Study population
Adult (!18 years) patients of either gender with solid tumors and chemotherapy-naïve who were planned to receive !2 cycles of HEC with cisplatin (single dose >50 mg/m 2 every 21 or 28 days) were eligible.
Exclusion criteria were as follows: (i) symptomatic brain metastases; (ii) scheduled to receive or having received, in the past 4 weeks, radiotherapy to upper abdomen or craniospinal region; (iii) emesis or significant nausea within 24 h before the first HEC cycle; (iv) coagulation disorders or current therapy with oral anticoagulants; (v) planned surgery during the study period or within 2 weeks after its conclusion; (vi) prior seizures; (vii) cannabinoids or current/past drug or alcohol abuse; (viii) use of other investigational drug(s) within 30 days before study entry or during the study; (ix) any relevant condition potentially interfering with study evaluation; (x) known hypersensitivity to ginger or any components of the product.
Concomitant medications taken during the study were recorded.
Procedures
After inclusion, patients were randomly assigned, according to a pre-defined computer generated list (RALLOC of STATA), to either ginger extract 40 mg/capsule (provided by Helsinn) or matching placebo (supplementary  Tables S1 and S2 , available at Annals of Oncology online). Randomization was stratified by center. Standard antiemetic treatment protocol for prevention of CINV in HEC, according to the guidelines by the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society of Medical Oncology (ESMO) [6] , consisting in a NK-1 receptor antagonist and a 5-HT3 receptor antagonist on day 1 and dexamethasone on days 1-4 was also provided. The defined dose of ginger was calculated according to [4] . The most effective dose of fresh root was 1 gr and the contents in shogaoil and gingerols in the CO 2 extract is close to the concentration of fresh root.
Patients were planned to receive !2 cycles of HEC, thus the duration of the study treatment ranged from 42 to 56 days, according to different chemotherapy schedules.
Each patient received two boxes, one for the first treatment period (from day 2 to day 21 or 28) and another for the second treatment period (from day 23 or 30 to day 42 or 56). Each box contained 8 blisters corresponding to 120 gelatin soft gel capsules containing vegetable oil (110 mg) and 40 mg of standardized Ginger CO 2 supercritical extract (title min in Gingerols: 16 mg, Min in Shogaoil 1.12 mg). Patients were instructed to take treatment per os 2 capsules in the morning and 2 in the late afternoon, with $150 ml of water or other liquids and on a full stomach. Dose modifications were not allowed.
All patients received a patient diary and the Functional Living Index Emesis (FLIE) [7] and Brief Fatigue Inventory (BFI) Questionnaire [8] . One and five days after each chemotherapy cycle, patients were contacted by phone to verify all procedures.
Assessments
The incidence and intensity of nausea was assessed using a Visual Analogue Scale (VAS, 0-100 mm), administered daily. The impact of nausea on daily life was measured through the FLIE questionnaire (score range 18-126), and the nausea and vomiting domain scores (score range 9-63). Higher scores indicate a greater ability to maintain daily life. A FLIE total score >108 indicates no impact on daily life. The impact of fatigue was assessed through the BFI questionnaire [range 0-10; higher scores indicate more fatigue; BFI can be categorized as follows: mild (1-3), moderate (4-6), or severe (7-10)]. Both questionnaires were completed at days 1 and 6 of the first and second cycle. Safety was assessed by monitoring adverse events (AEs), coded according to the Medical Dictionary for Regulatory Activities (MedDRA) dictionary.
Statistical analysis
In total, 250 patients were planned to be enrolled. Considering a possible 5% drop-out rate, a sample size of 236 valid patients is sufficient to provide !83% power to detect a 15% increase in the proportion of patients with no significant delayed nausea in the experimental group with respect to the control group, and a power of 71% to detect a 16% increase in the proportion of patients with no delayed nausea.
Primary end points, i.e. incidence of no nausea (VAS score <5 mm) and nonsignificant nausea (VAS score <25 mm), were assessed and compared between treatment groups using v 2 test. Delayed nausea (days 2-5), intercycle nausea (days 6-20/27) and anticipatory nausea (day 21/28) during each chemotherapy cycle were analyzed separately. Logistic regression was used to estimate odds ratios for the incidence of nausea. ANOVA was used to investigate differences in mean delayed, inter-cycle and anticipatory nausea between treatment groups and compliance to treatment. Regarding main secondary end points, the comparison between treatment groups concerning number of nausea episodes, FLIE scores and BFI score was carried out using ANOVA.
All randomized patients who took !1 dose of study treatment were included in the safety analysis. The number of patients with !1 AE, serious AE, and study product-related AE (defined as AEs with definite, probable, possible, unassessable or missing correlation with the study product) were summarized by treatment arm. Statistical analysis was carried out using STATA/IC 12.1 for Windows.
Results
Participants
In total, 251 patients were assigned to either ginger (n ¼ 125) or placebo (n ¼ 126) ( Figure S1 ); of these, 154 (61%) completed the study. Ninety-seven (39%) patients withdrew prematurely. The dropout rate did not differ between treatment groups (ginger: 42.4%; placebo 34.9%; P ¼ 0.22). Reasons for withdrawal were: AEs (n ¼ 25, 13 with ginger and 12 with placebo), withdrawal consent (n ¼ 24), lost to follow-up (n ¼ 1); protocol violations (n ¼ 2), and other (n ¼ 45; namely, changes to chemotherapy regimen (n ¼ 5 for ginger versus n ¼ 6 for placebo), patient's decision (14 versus 7), concomitant medications (n ¼ 1 for ginger), logistical problems (n ¼ 2 for each group), health status (n ¼ 3 for ginger), intolerance (n ¼ 5 for ginger). Placebo patients dropped for consent withdrawal more the ginger patients (31.8% versus 18.9%) and ginger patients dropped for other reasons more than placebo recipients (56.6% versus 34.2%). Seven subjects were excluded from efficacy and safety analysis as they did not take any dose of the assigned treatment.
Treatment groups did not differ significantly with respect to demographic or baseline measures (Table 1) . Lung cancer (LC) and head and neck cancer (HNC) were the most represented. Several chemotherapy schemes were used, but in every case cisplatin was combined with another drug with low or minimally emetogenic potential; almost all subjects (98.4%) were on 21-day regimen.
Efficacy: nausea and significant nausea
At baseline and at first day of cycle 2, no difference in nausea scores between the two groups was shown. In first cycle, the mean In the first cycle, the incidence of delayed nausea (odds ratio, OR 1.06, 95% CI 0.60/1.85, P ¼ 0.851), intercycle nausea (OR 1.31, 95% CI 0.73/2.37, P ¼ 0.367) and anticipatory nausea (OR 0.93, 95% CI 0.51/1.72, P ¼ 0.823) did not differ between the two arms (Table 2) . Similarly, no difference was observed in the second cycle (delayed nausea: OR 1.36, 95% CI 0.69/2.70, P ¼ 0.379; intercycle nausea: OR 1.32, 95% CI 0.68/2.58, P ¼ 0.417; anticipatory nausea: OR 1.20, 95% CI 0.58/2.47, P ¼ 0.629). The same pattern was observed for the incidence of significant nausea ( Table 3 ). The analysis by gender and by site of disease overall revealed a poorer control of nausea with ginger in men and in LC patients. In the ginger group men experienced a higher incidence of significant delayed and intercycle nausea (OR 2.74 95% CI 1.28/5.85 and OR 2.38 95% CI 1.04/5.44, respectively; P < 0.05). Among LC patients on ginger, a higher incidence of intercycle nausea (total and at first cycle) was observed (OR 2.77 95% CI 1.16/6.64; and OR 4.27 95% CI 1.60/11.37, respectively). At the second cycle, incidence of delayed nausea was higher among LC patients in the ginger group than those assigned to placebo (OR 2.67 95% CI 1.03/6.87; P ¼ 0.042). Analysis of the intensity revealed no difference in the mean nausea in both cycles and for each type of nausea (supplementary Table S3 , available at Annals of Oncology online).
Efficacy: protection from delayed nausea, impact of nausea on daily life activities (FLIE scores) and overall fatigue (BFI questionnaire), treatment compliance Overall, no difference was evident in FLIE and BFI scores between the ginger and placebo group. At first cycle, worsening of the BFI score was smaller with ginger than placebo (treatment difference À0.23, 95% CI: À0.97 to 0.51). At second cycle, the situation was different: worsening with ginger was slightly higher than with placebo (treatment difference 0.09, 95% CI -0.71 to 0.89). During both cycles, differences in BFI scores were negligible. A benefit of ginger over placebo in terms of FLIE score was identified in females (À7.31; 95% CI À14.56/À0.06, P ¼ 0.048) and in HNC patients (À7.43; 95% CI À14.42/À0.43, P ¼ 0.038). Treatment compliance did not differ between groups.
Safety
Of the 251 patients in the safety population, 198 (78.9%) experienced !1 AE, with no difference between ginger and placebo. Moreover, the AEs pattern of ginger was comparable to that of placebo. The most frequently reported AEs were gastrointestinal and general disorders, likely due to chemotherapy and the disease itself. The distribution of serious AEs between the treatment groups was also similar, with a lower number of events in the ginger group (15 versus 19) . A significant difference between the two treatment groups was found in AEs related to study treatment (63 with ginger and 35 with placebo). However, most treatment-related AEs in the ginger group were mild (51.1% versus 33.1% moderate and 13.8% severe; corresponding figures with placebo were 51.8%, 30.6% and 15.6%). Patients treated with ginger reported more gastrointestinal events than the placebo group (especially dyspepsia, abdominal and epigastric pain, hiccups) probably due to the organoleptic properties of ginger. Supplementary Table S4, available at Annals of Oncology online, reports information on serious AEs. The distribution of serious AEs was quite similar, with a lower number of events in the group treated with ginger (15 versus 19). Almost all serious events (n ¼ 29) were not related to treatment; the remaining five were classified as 'unassessable' or 'unlikely'.
Discussion
Investigations on the role of ginger in preventing CINV showed mixed results [3, 4] , likely due to the heterogeneity of the studies in terms of patients/disease characteristics and oncological treatments, lack of appropriate antiemetic treatment, nonhomogeneity of ginger dose and formulations. Therefore, in order to provide well-grounded evidence on the efficacy of ginger in this setting, we conducted this randomized, double blind, placebocontrolled trial to assess the impact of a standardized preparation of ginger in the prevention of nausea induced by HEC in patients with solid tumors naïve to chemotherapy.
Overall, ginger had no beneficial effect in reducing CINV (delayed, anticipatory and intercycle) associated with HEC. As such, ginger may not be suggested as a complementary therapy in this setting when the adequate guideline-driven preventive treatment is employed. However, the small sample size and some limitations of the study (e.g. incomplete reporting of data due to high dropout, not measuring the acute nausea) should be taken into account. Also, the possible interaction between aprepitant and ginger could be one of the reasons of the lack of efficacy, at least in the first days after chemotherapy [9] .
Nausea remains a major clinical issue in oncological patients [10] . Optimization of antiemetic therapy may therefore include new drugs in association with traditional approaches. The use of nutritional supplements and herbal therapy in oncology is increasing and there is a strong need to clarify their safety, activity and efficacy [11, 12] . This can be obtained through large and well-designed studies [13] . In this regard, strengths of the present trial include: the use of patient-reported validated tools, the administration of a standardized preparation of ginger, the evaluation of two consecutive chemotherapy cycles of cisplatin and the subsequent evaluation, for the first time, of intercycle nausea in a placebo-controlled arm. Daily ginger was safe, except for an increase in gastrointestinal symptoms. However, a high drop-out rate was documented in both arms: in line of principle, this finding can be interpreted as a further suggestion of modest efficacy. It should be considered that reasons for drop-out differ between the two arms: patients assuming placebo more frequently withdrew consent, while those on ginger more frequently interrupted for intolerance. This attrition could also be facilitated by the duration of treatment, which differed from other trials with antiemetics, usually evaluating drugs only in the first days of chemotherapy.
Subgroup analysis showed a moderate favorable effect of ginger on nausea in specific subgroups at higher emetic risk, namely women and HNC patients, when evaluated with the FLIE tool. Interestingly, female gender is a well-known risk factor for CINV and HNC patients who undergo chemo-radiotherapy are more prone to oral mucositis and taste dysfunctions, with increased risk of nausea [14] [15] [16] . On the other hand, a higher incidence of nausea was observed among men and LC patients treated with ginger. One could speculate that in patients with lower risk of CINV, namely the male subgroup, the higher gastrointestinal effects reported with ginger could have counterbalanced its possible beneficial effect. However, this analysis was not pre-planned, and patients were not stratified according to those factors. Therefore, these subgroup results should be considered as hypothesis-generating only.
Severe nausea and fatigue are common side-effects of cisplatinbased regimens and have been associated with cancer-related fatigue [17] . In our study, the analysis of BFI showed a lack of benefit for ginger.
In conclusion, ginger did not reduce the impact of nausea due to cisplatin throughout the two cycles of chemotherapy, without any benefit in delayed, anticipatory and intercycle assessments.
